A CCM device, short for cardiac contractility modulation device, is an implantable pulse generator that strengthens the heart’s contractions in people with heart failure. Unlike a pacemaker, which corrects irregular rhythms, or a defibrillator, which shocks the heart back into rhythm, a CCM device sends electrical signals that make each heartbeat more forceful. The only CCM device currently available is the Optimizer system, made by Impulse Dynamics, which received FDA approval in 2019.
How a CCM Device Works
The device delivers precisely timed electrical pulses to the heart muscle during a moment when the muscle is already contracting and cannot be triggered to beat again. This timing window is called the absolute refractory period. Because the signals arrive when the heart is already mid-beat, they don’t cause extra heartbeats or disrupt the rhythm. Instead, they change how the heart muscle cells handle calcium, the mineral that drives every contraction.
Specifically, the signals improve the way calcium flows into heart muscle cells and increase how sensitive the muscle fibers are to calcium. The result is a stronger squeeze with each beat. Over time, this also appears to reverse some of the harmful changes in gene activity that occur in failing hearts, essentially nudging the heart’s cellular machinery back toward healthier patterns.
The device runs on a preset schedule, delivering therapy in five one-hour sessions spread across each 24-hour period, with roughly four-hour rest periods between sessions. It also has built-in safety checks: on every single beat, it confirms that timing conditions are met before firing. If it detects a premature ventricular contraction (an irregular early beat), it skips that beat entirely to avoid any risk of triggering an abnormal rhythm.
Who Is Eligible for CCM Therapy
CCM is approved for people with moderate to moderately severe heart failure, specifically those classified as NYHA class III. That means people who are comfortable at rest but experience significant symptoms like shortness of breath or fatigue during ordinary activities like walking up stairs or carrying groceries. The heart’s pumping efficiency, measured as ejection fraction, needs to fall between 25% and 45%. A healthy heart typically ejects 55% to 70% of its blood with each beat, so this range represents meaningfully reduced function without being at the most severe end of the spectrum.
The key distinction is that CCM fills a gap for patients whose heart failure hasn’t responded adequately to medications but who don’t qualify for another common device therapy called cardiac resynchronization therapy (CRT). CRT works by coordinating the timing of the heart’s chambers and is designed for people whose hearts have a delayed electrical signal, shown on an EKG as a widened QRS complex (typically 120 milliseconds or longer). Many heart failure patients have a normal QRS duration, under 120 milliseconds, which means CRT won’t help them. CCM was specifically developed for this group.
What the Implantation Looks Like
The procedure resembles a pacemaker implantation in many ways. A surgeon makes a small incision, about 5 centimeters, below the collarbone on the right side of the chest. Two thin wires (leads) are threaded through a vein and guided into the right ventricle of the heart using real-time X-ray imaging. The leads are anchored into the wall separating the two ventricles, spaced at least 2 to 3 centimeters apart.
Once the leads are in place, the pulse generator is connected and tucked into a small pocket created just beneath the skin. The surgical team then wakes the patient to test that the leads are sensing and functioning correctly before closing the incision. Patients in reported cases have been discharged the following day.
Living with the Device
The Optimizer has a rechargeable battery, which sets it apart from most cardiac implants. You’ll need to recharge it once a week using an external charger placed on the skin over the device. A typical charging session takes about an hour, though it can run longer if the battery has been significantly depleted. The day and time don’t matter, but letting more than a week pass between charges risks draining the battery too far, which could require multiple daily sessions to recover.
Because the battery is rechargeable, the device lasts significantly longer than a standard pacemaker or defibrillator, which typically need surgical replacement every 5 to 10 years. The Optimizer’s pulse generator has a projected longevity of more than 15 years.
What the Evidence Shows
The largest trial supporting the device, called FIX-HF-5, enrolled 428 patients and compared CCM therapy plus standard medications against medications alone. CCM improved peak oxygen consumption, a key measure of how well the body can perform during exercise. In a smaller case series of 10 patients followed for six months, results were more dramatic: average ejection fraction improved from 27% to 35%, six-minute walk distance increased from 159 meters to 212 meters, and hospital admissions dropped by half.
Both the American Heart Association and the European Society of Cardiology acknowledge that CCM improves exercise capacity and quality of life. However, neither organization has issued a formal guideline recommendation, because current evidence does not yet show that the device reduces deaths or hospitalizations in large controlled trials. A newer trial called AIM HIGHer is underway to further evaluate these outcomes.
Who Should Not Get a CCM Device
Certain conditions rule out CCM therapy. People with permanent or long-standing persistent atrial fibrillation or flutter are not candidates, because the device relies on sensing consistent ventricular rhythms to time its signals safely. A mechanical tricuspid valve is also a contraindication, since the leads must pass through the tricuspid valve to reach the right ventricle. Patients without adequate venous access for lead placement, or those whose existing devices are programmed for continuous ventricular pacing, are similarly excluded.
How CCM Compares to Other Heart Failure Devices
A pacemaker maintains a steady heart rate by sending small electrical impulses that trigger beats when the heart’s own rhythm is too slow or unreliable. An implantable cardioverter-defibrillator (ICD) monitors for dangerously fast rhythms and delivers a shock to restore normal function. CRT uses a specialized pacemaker to synchronize the left and right sides of the heart in patients with electrical conduction delays.
CCM does none of these things. It does not pace, shock, or resynchronize. Its sole function is to make existing contractions stronger. This means it can be implanted alongside a pacemaker or ICD when needed, and it specifically serves patients who fall into the treatment gap where CRT is not an option due to a narrow QRS complex. For people with heart failure who remain symptomatic despite optimized medications and who don’t meet CRT criteria, CCM represents a device-based alternative that didn’t exist before 2019.